Welcome to our dedicated page for TREN news (Ticker: TREN), a resource for investors and traders seeking the latest updates and insights on TREN stock.
The TREN news page on Stock Titan aggregates company communications and press releases associated with Avant Technologies, Inc. (OTCQB: AVAI). These items describe how Avant combines artificial intelligence, biotechnology, and advanced computing to pursue healthcare and infrastructure initiatives. Readers can use this feed to review how the company portrays its progress across AI-driven diagnostics, cell-based therapies, and high-density compute platforms.
Recent news emphasizes Avant’s healthcare collaborations. Releases describe a joint venture with Austrianova’s affiliate SGAustria Pte. Ltd. called Klothonova LLC, focused on developing Klotho protein–producing cell lines and encapsulated cell systems for potential age-related disease and longevity therapies. Other announcements highlight work with Ainnova Tech, Inc. through Ai-nova Acquisition Corp., which advances the Vision AI platform for early detection of diabetic retinopathy and assessment of risks for conditions such as cardiovascular disease, type 2 diabetes, liver disease, and chronic kidney disease.
News items also cover Avant’s plans for AI infrastructure, including co-development with Wired4Tech, Inc. on high-density compute infrastructure and a distributed supercomputing network. Earlier releases outline the concept of an edge-native distributed supercomputer designed for AI software companies and big data workloads.
Investors and researchers following TREN-related activity can use this page to read about letters of intent for potential business combinations, expansion plans in diabetes programs, clinical trial preparation steps for Vision AI, and retractions or clarifications of prior announcements. Bookmark this page to access a consolidated view of how Avant Technologies describes its strategic direction in AI healthcare and AI infrastructure over time.
Avant Technologies (OTCQB: AVAI) and Austrianova launched joint venture Klothonova on Oct 21, 2025 to develop cell‑based therapies that overexpress the longevity protein Klotho.
R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and, when encapsulated in Austrianova’s Cell‑in‑Box, produced similar protein levels to non‑encapsulated cells. The JV is equally owned and will advance a GMP‑grade human cell clone toward preclinical and clinical studies; Austrianova is requalifying its ISO9001:2015 GMP isolator and preparing required documentation. The JV cites a cell therapy market projection of about $44 billion.
Avant Technologies (OTCQB: AVAI) has issued a retraction of its September 24, 2025 press release regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova. The company clarified that no binding agreement has been executed between the parties at this time.
The company acknowledged that the previous announcement contained statements issued in error and emphasized that any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones from the retracted release should not be relied upon. Avant Technologies expressed regret for any confusion caused and reaffirmed its commitment to providing accurate information to stakeholders.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced an enhanced patient recruitment strategy for their upcoming FDA clinical trial of the Vision AI platform, designed for early detection of diabetic retinopathy. The study will be conducted across 8-10 U.S. clinical sites, targeting approximately 1,000 multiethnic patients with diabetes.
The companies will collaborate with Fortrea, a renowned Contract Research Organization specializing in ophthalmology studies. The trial will focus on community clinics and primary care facilities rather than specialized centers to gather real-world data. This strategic approach aims to support the company's FDA 510(k) submission for Vision AI, with Ai-nova Acquisition Corp. (AAC) holding worldwide licensing rights for Ainnova's technology portfolio.
Avant Technologies (OTCQB: AVAI) announced plans to establish a new company focused on diabetes treatment expansion. This development follows their successful joint venture with Ainnova Tech through Ai-nova Acquisition Corp (AAC), which utilizes the Vision AI platform for detecting diabetic retinopathy and other diseases.
The company's Vision AI technology can identify early markers of various conditions, including diabetic retinopathy, which affects over 30% of diabetes patients. With over 500 million people globally living with diabetes, Avant aims to expand from diagnosis to treatment through potential joint ventures, partnerships, or acquisitions.
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech are expanding their joint venture, Ai-nova Acquisition Corp (AAC), across Latin America following Ainnova's participation in the 2025 Healthcare Innovation Summit in Mexico City. The expansion includes commercial pilots in Chile and Dominican Republic hospitals, focusing on demonstrating cost reduction in preventive diagnostics and improved healthcare efficiency.
The pilots utilize Ainnova's Vision AI platform for real-time health risk identification, enabling specialty care referrals. The joint venture plans to deploy an automated retinal imaging device integrated with AI to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images and basic health data.
AAC holds global licensing rights for Ainnova's technology portfolio. The companies are pursuing regulatory approvals in Brazil through MDSAP certification for ANVISA requirements, while simultaneously preparing for FDA clinical trials in the United States.
Summary not available.
Summary not available.
Summary not available.
Summary not available.